HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation.
Rudich
S M
SM
Department of Surgery, UC Davis Medical Center, Sacramento 95817, USA.
Mongini
P K
PK
Perez
R V
RV
Katznelson
S
S
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D019013:CD40 Antigens / Q000276:immunology / Q000502:physiology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology; D007700:Kinetics; D008213:Lymphocyte Activation / Q000187:drug effects*; D008934:Mitogens; D014066:Palatine Tonsil; D017035:Pravastatin / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D019821:Simvastatin / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D019013:CD40 Antigens; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008934:Mitogens; D011994:Recombinant Proteins; D015847:Interleukin-4; D019821:Simvastatin; D017035:Pravastatin